The results are in. Our expert panel has spoken. Please join us in congratulating the finalists for TopShock 2023!
Welcome to The Catalyst
Change isn't quick. Unless it's when you experience Intravascular Lithotripsy (IVL) for the first time. Stay apprised of our latest news and insights while discovering how a simple and intuitive tool can be The Catalyst to change the way you think about calcium modification.
The results are in. Our expert panel has spoken. Please join us in congratulating the finalists for TopShock 2023!
Topics: Coronary IVL, IVL Technology, SWAV News, Shockwave C2, Reimbursement
Kalzium ist nicht nur oberflächlich ... manchmal muss man in die Tiefe!
Topics: Coronary IVL, IVL Technology, Shockwave C2, Coronary Conferences
Over the past three months, Shockwave continued to ride a big wave of momentum with new product launches, inclusions in new journal articles, a pulse-racing presence at EuroPCR and more. The launch of Shockwave L6 Peripheral IVL Catheter in the U.S. came with physician-led case reviews, Q&As and more valuable content that demonstrate the big impact it can make in large peripheral vessels. We also turned up the heat at EuroPCR in Paris, where we showcased live cases, hosted an engaging symposium and participated in PCR TV interviews - all while focusing heavily on the European launch of our Shockwave C2+ Coronary IVL Catheter, which includes 50% more pulses than the original Shockwave C2. Dive right in and catch the wave of excitement in the latest issue of the PulsePoint newsletter!
Topics: Coronary IVL, Peripheral IVL, IVL Technology, Coronary Clinical Data, Peripheral Conferences, Peripheral Clinical Data, SWAV News, Shockwave C2, Coronary Conferences, Shockwave S4, PulsePoint Newsletter, Calcium Corner, Shockwave M5 & Shockwave M5+, Reimbursement, Treating Different Ca++ Morphologies, Female vs. Male Outcomes, Empower CAD
New Medicare Severity Diagnosis Related Groups (MS-DRGs) With Increased Payments Replace Temporary Payment Pathway for Coronary IVL Procedures Within the Hospital Inpatient Setting
Topics: Coronary IVL, IVL Technology, SWAV News, Shockwave C2, Reimbursement
It is a privilege to be recognized as one of Fast Company’s 2023 Best Workplaces for Women Innovators!
Topics: IVL Technology, SWAV News
Introducing the Shockwave Medical Direct Sales Team in the Great White North!
Topics: IVL Technology, SWAV News
Topics: Coronary IVL, IVL Technology, SWAV News, Shockwave C2
Hear from Dr. JD Corl, interventional cardiologist at The Christ Hospital (Cincinnati, Ohio) on how Shockwave L6 is changing the game for large calcified peripheral vessels.
Topics: Peripheral IVL
EuroPCR 2023 was a real blast for Shockwave Medical! Three sponsored sessions, two featured live cases,one interview on PCR TV andmany, many invaluable conversations at our booth. Thank you to all of you who attended for making this our best EuroPCR so far!
Topics: Coronary IVL, IVL Technology, Shockwave C2, Coronary Conferences
2023 was off to a shockingly great start! We were thrilled to acquire Neovasc, a company with a first-of-its-kind technology to address refractory angina, and are looking forward to driving value for physicians and improving the lives of an underserved patient population. The excitement for our new peripheral product, Shockwave L6, was electrifying and has continued to make waves across the U.S. Shockwave IVL and Coronary IVL became listed by SCAI as a potential therapy option across all U.S. cath labs regardless of surgical backup status. As always, we were further confirming the efficacy and safety of Shockwave IVL across different calcium morphologies through new publications. We highlight these topics and more in our latest PulsePoint Newsletter!
Topics: Coronary IVL, Peripheral IVL, IVL Technology, Coronary Clinical Data, Peripheral Conferences, Peripheral Clinical Data, SWAV News, Shockwave C2, Coronary Conferences, Shockwave S4, PulsePoint Newsletter, Calcium Corner, Shockwave M5 & Shockwave M5+, Reimbursement, Treating Different Ca++ Morphologies, Female vs. Male Outcomes, Empower CAD
But, right now we're in the early phases of the R&D program. In the meantime, don't miss the IVL application that heart teams are embracing already — maintaining transfemoral TAVR access through heavily calcified iliacs by using IVL.
